New treatment options for metastatic renal cell carcinoma

During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Vida, Alejo, Hutson, Thomas E, Bellmunt, Joaquim, Strijbos, Michiel H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519813/
https://www.ncbi.nlm.nih.gov/pubmed/28761748
http://dx.doi.org/10.1136/esmoopen-2017-000185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519813/
https://www.ncbi.nlm.nih.gov/pubmed/28761748
http://dx.doi.org/10.1136/esmoopen-2017-000185

Ejemplares similares